Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients

Completed · Phase 4

Conditions studied: Arteriovenous Fistula

In brief

This study will investigate how the use of Tranexamic acid and Bacitracin applied to the bleeding site after the hemodialysis fistula needle is removed will affect Time to Clot and Infection Rate

Key facts

Study ID

NCT02106962

Run by

California Institute of Renal Research

People needed

17

Starts

2014-04-01

Expected to finish

2014-08-01

Last updated by the study team

2017-09-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Dialysis patients with fistulas (native arterio-venous)

You may not qualify if…

• Previous sensitivity to or adverse reaction to Tranexamic acid or Bacitracin.
• Active infection.
• Stenosis of fistula.

Where it is running

• Fresenius Medical Care - Kearny Mesa — San Diego, California, United States
• California Insitute of Renal Research — San Diego, California, United States
• Fresenious Medical Care - Rancho — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.